HALIX B.V. signed an agreement with AstraZeneca for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine. HALIX will provide commercial manufacturing of drug substance at its cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX has expanded with two additional viral vector production lines. HALIX continues its key role as one of the original partners in the University of Oxford’s consort...